Protein Kinase Inhibitors: all 15,766 studies that test it
Page 25 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- Clinical Research of Tapering UDCA in PBC Patients With a Complete ResponseRecruitingNCT04650243Phase 4
- Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingNCT04645160Phase 1/2
- Ruxolitinib in Thrombocythemia and Polycythemia VeraRecruitingNCT04644211Phase 2
- KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MFRecruitingNCT04640532Phase 1/2
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingNCT04633239Phase 1
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaRecruitingNCT04625907Phase 1/2
- Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK InhibitionRecruitingNCT04619316Phase 2
- Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant AbemaciclibRecruitingNCT04614194Phase 2
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
- Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2
- Sirolimus for Graves' Orbitopathy (GO)Not yet recruitingNCT04598815Phase 2
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingNCT04598009Phase 2
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingNCT04591002Phase 2
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/2
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
- Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2
- Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary FibrosisRecruitingNCT04541680Phase 3
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
- Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in AdultsRecruitingNCT04501705Not applicable
- An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial CancerRecruitingNCT04492293Phase 2
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingNCT04486833Phase 1/2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingNCT04485559Phase 1
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid LeukemiaRecruitingNCT04471064Phase 1
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingNCT04469764Phase 2
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid TumorsRecruitingNCT04469530Phase 2
- Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyRecruitingNCT04467801Phase 2
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingNCT04455594Phase 2
- Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II StudyRecruitingNCT04454905Phase 2
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingNCT04449549Phase 2
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicable
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the KneeRecruitingNCT04433572Phase 3
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
- Study of Larotinib in Unresectable Advanced or Recurrent Esophageal CancerRecruitingNCT04415853Phase 3
- Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)Not yet recruitingNCT04406870Phase 4
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
- A Study of KC1036 in Patients with Advanced Solid TumorsRecruitingNCT04387916Phase 1
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04353375Phase 2/3
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingNCT04333108Phase 3
- Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaRecruitingNCT04331093Phase 2
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2
- Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerRecruitingNCT04322617Phase 2/3
- Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingNCT04322578Phase 2
- Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantRecruitingNCT04322383Phase 2
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingNCT04319484Phase 2/3
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingNCT04307576Phase 3
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingNCT04305834Phase 2
- Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic AdenocarcinomaRecruitingNCT04303403Phase 1
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
- AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingNCT04298008Phase 2
- A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingNCT04293562Phase 3
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
- Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)RecruitingNCT04278222Phase 2
- Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy ParticipantsRecruitingNCT04271488Phase 1
- Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Phase 1/2
- Adjuvant Study of Pyrotinib in HER-2 Positive Breast CancerRecruitingNCT04254263Phase 3
- A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04243785Phase 1
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2
- Cabozantinib to Treat Recurrent Liver Cancer Post TransplantRecruitingNCT04204850Phase 2
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNCT04199026Not applicable
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid TumorRecruitingNCT04192344Phase 1
- MS-553 in Diabetic Retinopathy Patients With Central Involved Macular EdemaRecruitingNCT04187443Phase 1
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingNCT04183712Phase 2
- FES Imaging to Optimize Tamoxifen for Metastatic Breast CancerRecruitingNCT04174352Early Phase 1
- Erlotinib for Hepatocellular Carcinoma ChemopreventionNot yet recruitingNCT04172779Phase 2
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruitingNCT04166409Phase 3
- Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerNot yet recruitingNCT04158856Phase 2
- Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid MalignanciesRecruitingNCT04149691Phase 1
- Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationNCT04138927Phase 3
- Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCRecruitingNCT04136535Phase 2
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingNCT04116502Phase 3
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
- A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid TumorsRecruitingNCT04093466Phase 1
- Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesRecruitingNCT04092673Phase 1/2
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingNCT04090567Phase 2
- Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersRecruitingNCT04079179Phase 2
- MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingNCT04074564Early Phase 1
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingNCT04061512Phase 2/3
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingNCT04061421Phase 1/2
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingNCT04055649Phase 2
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasRecruitingNCT04055220Not applicable
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
- Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in SituRecruitingNCT04046159Phase 3
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationRecruitingNCT04040205Phase 2